Comments on the FDA’s February 2019 Orange Book raw data
In mid-March the FDA released their February 2019 (Vol. 39, Supp. 2) Orange Book raw data. I updated my Orange Book Companion® right away, but here are a few somewhat overdue observations about Supplement 2:
We had another light month of patent listings. Only 36 new patents were listed in February. Are we still in a New Years hangover? Unlike last month no single product dominated the new listings.
Three patents were delisted well before their expiration dates. I could not find any IPR decisions or patent listing disputes for those patents. One NDA holder delisted two of those patents from one of its products and listed them for another of its products. Maybe just a mix up during the listing process? If so, this is another example of why companies need to pay special attention to their end-to-end patent listing workflow.
Pfizer received a three-year “miscellaneous” exclusivity (M-237) for CHANTIX based upon their completion of a study “to determine whether varenicline, as part of an overall smoking cessation program, is effective in achieving and maintaining smoking cessation in tobacco-addicted adolescents, ages 12 through 16, inclusive.” [Approval letter, Feb. 22, 2019].
OMG! With so many decades of warnings about the adverse health effects of tobacco why is such a study still needed? Well, these days it is not only cigarettes that are grabbing the attention of youngsters. FDA Commissioner Gottlieb released a statement on March 4 in which he said that “the number of children using e-cigarettes remains at epidemic levels.” So a drug that could help wean young people off any nicotine-containing product would be welcome.
Unfortunately, Pfizer’s study in adolescent cigarette smokers did not show that Chantix was effective in that age group. As a result of this study, the first sentence of Section 8.4 “Pediatric Use” of the Chantix label was changed from: